Jan 11, 2022 / 09:30PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Perfect. Good afternoon, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JPMorgan. It's my pleasure to introduce our next company, Bio-Rad. So this session will be a 40-minute fireside chat. (Operator Instructions)
And with that, we can get started. So thank you, Norman, and Ilan and Andy for joining us today. To kick it off, we could just talk about, in general, the strength that you guys have seen in the past 2 years.
Questions and Answers:
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - AnalystSo the strength that you guys have seen has been in partly due to strong contribution from COVID-related sales. So with new variants likely to continue to emerge, how should we be thinking about the durability of your revenue in the coming year? And then what do you see for '23 and beyond?
Andrew J. Last - Bio-Rad Laboratories, Inc. - Executive VP & COO